Company Explorer

India's largest pharma company, transitioning from generics to a global specialty franchise across dermatology, ophthalmology and onco-derm while retaining a large India and US generics base.

One of the world's largest API makers with a high-margin custom-synthesis (CDMO) arm serving innovators; benefiting from China+1 and new contrast-media/peptide capex.

High-margin, brand-led franchise dominated by India chronic therapies (cardiac, CNS, GI) plus Brazil and Germany; consistent M&A integrator (Unichem, Curatio, JB Pharma bid).

Respiratory-led franchise with a strong India brand portfolio, US inhalation/peptide complex generics (gAdvair, gAbraxane) and a meaningful emerging-markets/SAGA presence.

Diversified player with a large US generics engine, India branded + consumer wellness (Nutralite, Glucon-D), biosimilars and a novel drug (Saroglitazar) franchise.

Vertically integrated generics major with a strong US complex-generics pipeline, growing biosimilars, and an API/services (PSAI) arm. Pursuing nutrition/consumer and GLP-1 opportunities.

Turnaround driven by US complex generics (gSpiriva/Tiotropium, Albuterol) and an India chronic franchise; margin recovery on cost discipline and complex launches.

Domestic-focused powerhouse with strong consumer healthcare brands and deep rural/Tier-2-4 distribution; expanding chronic and inorganic (Bharat Serums) into specialty/injectables.

Scale generics manufacturer with deep API backward integration, expanding into injectables, biosimilars, and a large Penicillin-G (PLI) backward-integration project.

Transitioning from an ARV API base to a diversified CDMO/CRDMO platform across small molecules, biologics and crop science, with heavy capex now monetizing.

India's biosimilars pioneer with a global commercial biosimilars franchise (post-Viatris acquisition), a generics/API arm, and a majority stake in Syngene.

Leading India acute company (top anti-infective franchise — Clavam, Pan) diversifying into chronic and a profitable US generics business.

Premium MNC branded franchise (Thyronorm, Udiliv, Duphaston, Cremaffin) with category leadership in GI, thyroid and women's health; cash-rich consistent compounder.

High-quality, brand-led franchise across emerging markets and India with strong first-to-market specialty launches; disciplined capital allocation and high return ratios.

MNC pharma with a high-margin India branded portfolio and a fast-growing premium vaccines franchise; asset-light, dividend-rich model.

KKR-owned brand-led franchise with top India cardiac/chronic brands, an acquired in-licensed portfolio, and a global contract lozenge manufacturing business.

Diversified platform: integrated global CDMO (discovery to commercial, ADC capability), complex hospital generics, and an India consumer healthcare brand portfolio.

Niche, complex-chemistry specialist with a fast-scaling CMS (CDMO) franchise, including peptides; valued for innovator project pipeline and execution quality.

MNC branded portfolio (Prevenar, Magnex, Minipress) with a vaccine franchise; high cash generation but slower growth and portfolio-renewal questions.

Pure-play India branded company concentrated in chronic cardio-metabolic therapies; aggressively building derma, nephrology and injectables via acquisitions (Biocon-derma, Swiss Parenterals, Bharat Serums-linked).

Scale, cost-leadership player vertically integrated across API, pellets/granules (PFI) and finished dosages for high-volume molecules; moving into higher-value extended-release and new sites.

India's leading integrated research & manufacturing services platform (Biocon group), serving global biopharma from discovery through commercial supply across small molecules & biologics.

Niche, high-return company built on a unique LatAm front-end distribution model now layering on a fast-growing US sterile injectables and ophthalmic franchise.

High-margin innovator-focused CDMO, merged with Cohance Lifesciences under Advent to build a broad small-molecule + ADC + agro CDMO platform (listed entity renamed Cohance).

Diversified mid-cap with a large US ANDA portfolio across oral solids, derm, ophthalmic and injectables, an India branded business, and API; post heavy-capex margin-recovery phase.